Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.

Inclusion Criteria:

• Aged 18-70,
• smoking > 10 cigarettes per day,
• no current major depression,
• no concurrent psychiatric medications

Exclusion Criteria: